These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19572445)

  • 1. [Pharmacoeconomic aspects of lopinavir/ritonavir monotherapy].
    Escobar Rodríguez I; Esteban Alba C
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():47-51. PubMed ID: 19572445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Lopinavir/ritonavir monotherapy as a simplification strategy in the treatment of HIV-1 infection].
    Pulido Ortega F; Llenas-García J
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():12-20. PubMed ID: 19572439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Simpson KN; Luo MP; Chumney EC; King MS; Brun S
    Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacoeconomic analysis of a maintenance strategy with lopinavir/ritonavir monotherapy in HIV-infected patients].
    Escobar I; Pulido F; Pérez E; Arribas JR; García MP; Hernando A
    Enferm Infecc Microbiol Clin; 2006 Oct; 24(8):490-4. PubMed ID: 16987465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
    Simpson KN; Jones WJ; Rajagopalan R; Dietz B
    Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice].
    Moltó J; Clotet B
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():24-6. PubMed ID: 19572441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lopinavir/ritonavir monotherapy. Possible indications].
    López Aldeguer J
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():21-3. PubMed ID: 19572440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.
    Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kaletra OK'd by FDA.
    James JS
    Posit Living; 2000 Nov; 9(9):8, 13. PubMed ID: 12154764
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.
    Simpson KN; Jones WJ; Rajagopalan R; Dietz B
    Clin Drug Investig; 2007; 27(12):807-17. PubMed ID: 18020538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
    Broder MS; Chang EY; Bentley TG; Juday T; Uy J
    J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Civil society strategy for the compulsory licensing of lopinavir/ritonavir: the Brazilian case.
    Vieira MF; Reis R; Chaves G
    HIV AIDS Policy Law Rev; 2008 Dec; 13(2-3):80-1. PubMed ID: 19297771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lopinavir/ritonavir. (Kaletra).
    Res Initiat Treat Action; 2000 Dec; 6(4):16-8. PubMed ID: 11708169
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of Markov model and discrete-event simulation techniques for HIV.
    Simpson KN; Strassburger A; Jones WJ; Dietz B; Rajagopalan R
    Pharmacoeconomics; 2009; 27(2):159-65. PubMed ID: 19254048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lopinavir/ritonavir monotherapy in the treatment of HIV infection. Introduction].
    Pulido Ortega F; Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():1. PubMed ID: 19572436
    [No Abstract]   [Full Text] [Related]  

  • 16. [Ritonavir-boosted lopinavir monotherapy due to intolerance to nucleoside reverse transcriptase inhibitors in an HIV-infected paediatric patient].
    Espiau M; Soler-Palacín P; Borrull A; Figueras C
    Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):319. PubMed ID: 21334110
    [No Abstract]   [Full Text] [Related]  

  • 17. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression.
    Chan-Tack KM; Edozien A
    J Acquir Immune Defic Syndr; 2006 Apr; 41(4):531-2. PubMed ID: 16652066
    [No Abstract]   [Full Text] [Related]  

  • 18. Improving access to second-line antiretrovirals.
    The Lancet
    Lancet; 2007 Apr; 369(9570):1320. PubMed ID: 17448798
    [No Abstract]   [Full Text] [Related]  

  • 19. [Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS].
    Galegov GA
    Antibiot Khimioter; 2007; 52(1-2):42-5. PubMed ID: 18461809
    [No Abstract]   [Full Text] [Related]  

  • 20. [Kaletra (lopinavir/ritonavir--a new HIV protease inhibitor].
    Ershov FI; Kas'ianova NV; Vasil'ev AN
    Antibiot Khimioter; 2002; 47(11):27-9. PubMed ID: 12698577
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.